Status:
RECRUITING
Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
Lead Sponsor:
Wenjin Yin
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Eligibility Criteria
Inclusion
- Aged ≥18 and older
- Patients with pathologically confirmed breast cancer without distant metastasis or local recurrence
- HR+/HER2-
- ECOG 0-3
- Subjects meeting current guideline recommendations and planning to receive adjuvant CDK4/6 inhibitors
Exclusion
- During pregnancy or lactation
- Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption
Key Trial Info
Start Date :
August 28 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2033
Estimated Enrollment :
229 Patients enrolled
Trial Details
Trial ID
NCT07180056
Start Date
August 28 2025
End Date
February 1 2033
Last Update
November 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China, 200127